BRAFTOVI (Pierre Fabre Australia Pty Ltd)
Product name
BRAFTOVI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
112 (175 working days)
Active ingredients
encorafenib
Registration type
EOI
Indication
Non-small cell lung cancer (NSCLC)
Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer with a BRAF V600E mutation.